5-Amino-1MQ is the short name commonly used for 5-amino-1-methylquinolinium iodide, a quinolinium small molecule studied as an inhibitor of nicotinamide N-methyltransferase (NNMT).

The iodide salt (1:1 salt of the 5-amino-1-methylquinolinium cation with iodide, PubChem parent CID 950107) has the molecular formula C10H11IN2, a molecular weight of 286.11 g/mol, an exact mass of 285.99670 Da, and CAS number 42464-96-0.[1]
Published evidence for 5-Amino-1MQ comes mainly from enzyme tests, cultured cells, and mouse studies. These results do not show that the compound is safe or effective in people or animals outside an approved research setting.
Basic Information
| Item | Information |
|---|---|
| Common research name | 5-Amino-1MQ |
| Chemical name | 5-Amino-1-methylquinolinium iodide (1:1 salt of the 5-amino-1-methylquinolinium cation with iodide)[1] |
| CAS number | 42464-96-0 |
| Molecular formula | C10H11IN2 |
| Molecular weight | 286.11 g/mol for the iodide salt; exact mass 285.99670 Da[1] |
| Compound type | Quinolinium small molecule; not a peptide |
| Main research target | Nicotinamide N-methyltransferase (NNMT) |
| Reported enzyme IC50 | About 1.2 µM in a published NNMT biochemical assay; this value depends on the assay conditions[3] |
| Intracellular EC50 (adipocytes) | 2.3 ± 1.1 µM for 1-MNA reduction in differentiated 3T3-L1 adipocytes (R² = 0.94)[4] |
Because 5-Amino-1MQ has no amino-acid chain or peptide bonds, it should not be described as a peptide. When the iodide salt is used, molar calculations should be based on 286.11 g/mol rather than the mass of the quinolinium cation alone.
How NNMT Works
NNMT is a cytosolic enzyme encoded by the NNMT gene at chromosomal location 11q23.2. The gene spans approximately 55.7 kb across 8 exons and codes for a protein in the NNMT/PNMT/TEMT family (EC 2.1.1.1).
NNMT is expressed most highly in human liver (RPKM 188.3), followed by the appendix (RPKM 69.3) and approximately ten other tissues, with a biased expression pattern.[2]
NNMT transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide. This reaction forms 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH).[2]
Nicotinamide + SAM → 1-MNA + SAH
This reaction matters to researchers for two simple reasons. It uses nicotinamide, which is linked to the cellular NAD+ pathway, and it also uses SAM, which supplies methyl groups for many other reactions in cells.
Because NNMT consumes both nicotinamide and SAM, inhibiting the enzyme may alter intracellular 1-MNA, NAD+, SAM, and SAH levels under some experimental conditions. The direction and magnitude of these changes depend on the cell type, inhibitor concentration, exposure time, and assay design.
How 5-Amino-1MQ Affects NNMT
A 2017 medicinal-chemistry study screened N-methylated quinolinium, isoquinolinium, pyridinium, and benzimidazolium/benzothiazolium analogues for NNMT inhibition. The screening identified quinoliniums as a promising scaffold, and 5-Amino-1MQ emerged as one of the most active compounds with an IC50 of approximately 1.2 µM under the biochemical assay conditions used.
The study developed comprehensive structure-activity relationships across analogues with a >1,000-fold range of activity, and computer-based docking of inhibitors to the NNMT nicotinamide-binding site revealed selective binding to substrate-binding-site residues and essential chemical features driving the protein-ligand intermolecular interactions.[3]
A 2018 follow-up study further characterized 5-Amino-1MQ in cell-based assays and reported the following selectivity profile against other methyltransferases and related enzymes at concentrations up to 600 µM: no detectable inhibition of DNMT1, PRMT3, or NAMPT; a maximum of approximately 10% inhibition of COMT at 600 µM (no curve could be fitted); and no inhibition of SIRT1 at 300 µM. These results support a useful selectivity window for NNMT research, but they were obtained with a limited panel of related enzymes and do not rule out every possible off-target interaction.[4]
An IC50 is an enzyme-test result, not a dosing value. It can change when the amount of enzyme, substrate, SAM, test time, or detection method changes.
It should not be used as a human, veterinary, or model-animal dosing guide.
Findings from Cell Experiments
In the 2018 study, 5-Amino-1MQ was assessed for membrane permeability using a PAMPA assay, which gave a passive permeability of 3.01 × 10−6 cm/s. A Caco-2 bidirectional transport assay showed an apparent permeability (Papp) of 34.2 × 10−6 cm/s from apical to basolateral and 45.2 × 10−6 cm/s from basolateral to apical, with an efflux ratio of 1.33, indicating high permeability and no significant efflux.[4]
In differentiated 3T3-L1 mouse adipocytes, 5-Amino-1MQ lowered intracellular 1-MNA in a concentration-dependent manner with an EC50 of 2.3 ± 1.1 µM (R² = 0.94). At 10–60 µM, 1-MNA stabilised at approximately 40% of control levels.
In the same concentration range (0.3–60 µM), intracellular NAD+ increased approximately 1.2- to 1.6-fold, with 10 µM reaching statistical significance (P < 0.05 vs control). SAM showed a concentration-dependent increase that reached significance at 30 µM (P < 0.05), while nicotinamide and SAH levels did not change significantly across the tested range.[4]
In a lipid-accumulation assay during adipocyte differentiation, 5-Amino-1MQ at 30 µM reduced lipid accumulation by approximately 50% (P = 0.0001), and at 60 µM by approximately 70% (P = 0.0001). MTT-based viability testing showed no effect at 10 µM (24 h), moderate cytotoxicity at 100–300 µM, and approximately 40% cytotoxicity at 600 µM.[4]
These results show that NNMT inhibition can change related metabolites in this cell model. They do not by themselves prove that 5-Amino-1MQ activates sirtuins, increases mitochondrial activity, changes specific histone marks, or switches on a complete fat-burning pathway.
Those claims require separate measurements.
Findings from Mouse Studies
A 2014 study used an antisense oligonucleotide method to lower NNMT expression in white adipose tissue and liver of diet-induced obese mice. The study reported changes in fat mass, body weight, and energy-related measurements.
This was a gene-silencing experiment, not a 5-Amino-1MQ experiment, so the two methods should not be described as identical.[5]
A later study tested 5-Amino-1MQ in male diet-induced obese C57Bl/6 mice (17 weeks old, approximately 38 g starting body weight, 16 weeks on a 45% fat diet). The compound was administered subcutaneously at 20 mg/kg three times daily (total daily dose approximately 60 mg/kg, calculated on a free-base basis) for 11 days.
Over this period, the 5-Amino-1MQ group lost 2.0 ± 0.6 g (approximately 5.1% of starting body weight), while the vehicle control group gained 0.6 ± 0.4 g (P = 0.0028 for the treatment main effect; treatment × time interaction P < 0.0001). Significant differences emerged by day 6 and persisted through day 11.[4]
Total cumulative food intake did not differ significantly between groups (28.1 ± 1.2 g for controls vs 26.2 ± 1.4 g for treated mice, P > 0.05), indicating that weight loss was not driven by appetite suppression. At the end of the study, epididymal white adipose tissue mass was reduced by approximately 35% (P < 0.001), adipocyte area was reduced by more than 30% (P < 0.05), and total plasma cholesterol (4 h fasted) was approximately 30% lower than controls (P < 0.05), approaching levels seen in age-matched standard-chow-fed C57Bl/6 mice.
No adverse behavioural or toxicological observations were reported at the pharmacologically effective doses.[4]
The original mouse procedure used repeated subcutaneous administration under an approved animal-research protocol. Exact doses and administration steps are reproduced here only as literature context and must not be adapted for human or veterinary use.
What the Research Does Not Prove
- It does not prove safety or effectiveness in humans.
- It does not establish a medical, dietary, cosmetic, or veterinary use.
- It does not show that every downstream change is caused only by NNMT inhibition.
- It does not make genetic NNMT knockdown and small-molecule inhibition the same experiment.
- It does not allow an enzyme IC50 or a cell-culture concentration to be converted into a dose.
Laboratory Handling Notes
Handling instructions should come from the batch-specific certificate of analysis, safety data sheet, and the laboratory’s own approved procedures. A fixed stock concentration or solution-storage period should not be stated unless it has been supported by solubility and stability data for the exact salt form and batch.
- Check the salt form: use 286.11 g/mol for molar calculations when the material is the iodide salt (exact mass 285.99670 Da).
- Check solubility: do not assume that a high-concentration stock will fully dissolve in water or DMSO.
- Check solution stability: storage instructions for dry powder do not automatically apply to a prepared solution.
- Use a vehicle control: keep the solvent level the same in treated and control samples.
- Confirm concentration when needed: a clear-looking solution does not by itself prove full dissolution or the correct concentration.
How to Read the COA
A certificate of analysis should refer to the exact batch being supplied. It should not be replaced by a general product page or a COA from another lot.
For a small-molecule research reagent, the COA should normally include the batch number, an identity test, and a purity test. HPLC can show the relative size of detected chromatographic peaks, but HPLC area percentage alone does not confirm the chemical identity or account for every possible impurity.
Identity is better supported by a separate method such as mass spectrometry or NMR. Because 5-Amino-1MQ is a small molecule (not a peptide), peptide-related quality attributes such as amino-acid sequence, peptide content by sequence, TFA/acetate counterion ratios, or peptide-specific impurity profiles do not apply.
ICH Q2(R2) explains general principles for checking whether an analytical method is suitable and reliable; it is used here only as a general analytical-science reference and does not automatically establish mandatory release specifications for an RUO research reagent.[6]
Water content and residual solvents should be reported when they are relevant to the manufacturing process, material form, or concentration calculation. ICH Q3A(R2) describes general impurity categories for chemically synthesized substances, and ICH Q3C(R9) describes the control of residual solvents; both are cited here as general analytical-quality references and do not make 5-Amino-1MQ a pharmaceutical ingredient.[7][8]
A research-grade COA does not prove human safety, clinical effectiveness, sterility, endotoxin control, or suitability for any non-research use.
References
- NIH PubChem. NNMTi, CID 66522933 (5-amino-1-methylquinolinium iodide). https://pubchem.ncbi.nlm.nih.gov/compound/NNMTi
- NCBI Gene. NNMT nicotinamide N-methyltransferase, Gene ID 4837 (11q23.2, 8 exons, EC 2.1.1.1). https://www.ncbi.nlm.nih.gov/gene/4837
- Neelakantan H, Wang HY, Vance V, Hommel JD, McHardy SF, Watowich SJ. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. Journal of Medicinal Chemistry. 2017;60(12):5015-5028. doi:10.1021/acs.jmedchem.7b00389. https://pubmed.ncbi.nlm.nih.gov/28548833/
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141-152. doi:10.1016/j.bcp.2017.11.007. https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. doi:10.1038/nature13198. https://pmc.ncbi.nlm.nih.gov/articles/PMC4107212/
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf
- International Council for Harmonisation. ICH Q3A(R2): Impurities in New Drug Substances. https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf
- International Council for Harmonisation. ICH Q3C(R9): Impurities—Guideline for Residual Solvents. https://database.ich.org/sites/default/files/ICH_Q3C%28R9%29_Guideline_MinorRevision_2024_2024_Approved.pdf
Research Use Only Disclaimer
Research Use Only: The 5-Amino-1MQ product described on this page is supplied for laboratory research purposes only and is not approved for human or veterinary use. This article summarizes published preclinical findings and analytical-quality considerations.
It does not provide medical advice, dosing instructions, administration guidance, or preparation procedures.